Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | ARID1A G1450fs |
| Gene Variant Detail | |
| Relevant Treatment Approaches | EZH2 inhibitor |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| ARID1A G1450fs | urinary bladder cancer | sensitive | EZH2 inhibitor | Tulmimetostat | Preclinical - Cell culture | Actionable | In a preclinical study, Tulmimetostat inhibited viability in 5/6 bladder cancer cell lines harboring ARID1A loss of function mutations including ARID1A G1450fs in culture (PMID: 38833522). | 38833522 |